share_log

信達生物：截至2023年12月31日止月份之股份發行人的證券變動月報表

INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

香港交易所 ·  Jan 5 09:55
Summary by Moomoo AI
信達生物製藥於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司普通股的法定/註冊股份數目維持在5,000,000,000股，而法定/註冊股本總額為50,000美元，本月無變動。已發行股份方面，本月底結存為1,621,830,905股，較上月增加3,827,500股。該增加主要來自於股份期權計劃的行使，其中包括首次公開發售前股份獎勵計劃和首次公開發售後僱員持股計劃。本月內因行使期權所得資金總額為6,867,714.06港元。公司確認所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
信達生物製藥於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司普通股的法定/註冊股份數目維持在5,000,000,000股，而法定/註冊股本總額為50,000美元，本月無變動。已發行股份方面，本月底結存為1,621,830,905股，較上月增加3,827,500股。該增加主要來自於股份期權計劃的行使，其中包括首次公開發售前股份獎勵計劃和首次公開發售後僱員持股計劃。本月內因行使期權所得資金總額為6,867,714.06港元。公司確認所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
Sinda Biopharmaceuticals filed with Hong Kong Trading and Clearing Limited on 5 January 2024 with the Securities Monthly Change Report for the year ended 31 December 2023. The report showed that the number of regulary/registered shares of the company's common stock remained at 5,000,000,000 shares, with a total regulated/registered share capital of $50,000, unchanged this month. In terms of issued shares, 1,621,830,905 shares outstanding at the end of the month, an increase of 3,827,500 shares compared to the previous month. The increase resulted primarily from the exercise of share option schemes, which include the Initial Public Offering Pre-IPO Share Award Scheme and the Employee Stock Holding Scheme after the Initial Public Offering. The total amount of capital gained from the exercise of options during the month was HK$6,867,714.06. The Company confirms that all securities issuance has been approved by the Board of Directors and complies with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Sinda Biopharmaceuticals filed with Hong Kong Trading and Clearing Limited on 5 January 2024 with the Securities Monthly Change Report for the year ended 31 December 2023. The report showed that the number of regulary/registered shares of the company's common stock remained at 5,000,000,000 shares, with a total regulated/registered share capital of $50,000, unchanged this month. In terms of issued shares, 1,621,830,905 shares outstanding at the end of the month, an increase of 3,827,500 shares compared to the previous month. The increase resulted primarily from the exercise of share option schemes, which include the Initial Public Offering Pre-IPO Share Award Scheme and the Employee Stock Holding Scheme after the Initial Public Offering. The total amount of capital gained from the exercise of options during the month was HK$6,867,714.06. The Company confirms that all securities issuance has been approved by the Board of Directors and complies with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more